1. FRI0182 A Single Dose Study Comparing Pharmacokinetics, Safety, and Immunogenicity of M923 (A Proposed Biosimilar To Adalimumab), US-Sourced Adalimumab, and EU-Sourced Adalimumab in Healthy Subjects. (15th July 2016) Authors: Hillson, J.; Mant, T.; Ganguly, T.; Rosano, M.; Huntenburg, C.; Alai-Safar, M.; Darne, S.; Palmer, D.; Pavlova, B.; Doralt, J.; Reeve, R.; Goel, N.; Weilert, D.; Rhyne, P.; Caminis, J.; Roach, J. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 495 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. THU0079 Polypharmacy, Although not Combination Dmard Therapy, in Rheumatoid Arthritis is Associated with Increased Hospitalisation Risk. (9th June 2015) Authors: Filkova, M.; Ibrahim, F.; Norton, S.; Scott, D.; Mant, T.; Cope, A.; Molokhia, M.; Galloway, J. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 220 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗